- Publishing research in peer-reviewed journals plays a central role in ensuring the credibility and reliability of scientific findings.
- Companies that consistently publish their findings often strengthen their credibility with both regulators and the medical community.
- Most recently, SNGX announced that a clinical summary of its HyBryte(TM) therapy for cutaneous T-cell lymphoma was published in the peer-reviewed journal “Expert Opinion on Investigational Drugs.”
The publication of clinical research in peer-reviewed journals remains a critical milestone in drug development, offering independent validation and broader visibility for emerging therapies. Soligenix (NASDAQ: SNGX) recently reached such a milestone with the publication of a clinical summary of its HyBryte(TM) therapy, reinforcing the importance of scientific transparency as the company advances treatments for rare diseases.
Publishing research in peer-reviewed journals plays a central role in ensuring the credibility and reliability of scientific findings. Peer review serves as a quality control mechanism that evaluates the validity, significance and originality of research before it is disseminated to the broader scientific community, helping to maintain high standards in biomedical science. This process is particularly important in drug development, where clinical data must be rigorously scrutinized before gaining acceptance among clinicians, regulators and investors.
In addition to validating research, publication also facilitates knowledge sharing and scientific progress. Peer-reviewed publications allow researchers to build upon existing findings, supporting cumulative advancements in medicine and improving patient care outcomes over time. For biopharmaceutical companies, publishing clinical data can therefore help position therapies within the broader scientific landscape while enabling collaboration and informed clinical decision-making.
“Transparency of clinical trial information . . . is essential to scientific advancement,” states the Commissioner of Food and Drugs, Robert M. Califf, M.D. “Making clinical trial information publicly available fulfills the commitment to volunteer research participants and also enhances public trust. Simply put: if a human experimental study is done and the existence of the study and the results are not publicly available, it is difficult to assert that obligation of the researchers to contribute to generalizable knowledge has been met.”
Companies that consistently publish their findings often strengthen their credibility with both regulators and the medical community. Soligenix is one of those companies. Most recently, SNGX announced that a clinical summary of its HyBryte therapy (synthetic hypericin) for cutaneous T-cell lymphoma (“CTCL”) was published in the peer-reviewed journal “Expert Opinion on Investigational Drugs.”
Titled “Topical Hypericin: A Promising Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma,” the article was written by Brian Poligone, MD, PhD, the founder and medical director of the Rochester Skin Lymphoma Medical Group; Poligone is also the director of cancer biology research for the Rochester General Hospital Research Institute. Poligone and his team have participated in four HyBryte clinical studies and have gained extensive clinical experience and understanding of the HyBryte therapy. The publication provides an overview of the therapy’s mechanism of action, clinical development and potential role in treating CTCL, a rare form of non-Hodgkin lymphoma that primarily affects the skin.
CTCL is a chronic condition that can significantly impact quality of life, often presenting with persistent skin lesions, itching and inflammation. CTCL is typically slow growing but requires ongoing management, with treatment strategies often focused on controlling symptoms and delaying disease progression. This underscores the need for therapies that are both effective and well tolerated over long periods.
HyBryte is designed as a photodynamic therapy that combines synthetic hypericin, a photosensitizing agent, with visible light activation. Once applied to affected areas, the compound is activated by specific wavelengths of light, producing a localized therapeutic effect that targets malignant T-cells while minimizing damage to surrounding healthy tissue. Soligenix has reported that this approach may offer a non-systemic treatment option, which is particularly relevant in early-stage CTCL where patients often seek therapies with fewer systemic side effects.
The published clinical summary highlights data generated from HyBryte’s clinical development program, including prior late-stage trials evaluating its safety and efficacy profile. By consolidating these findings into a peer-reviewed format, the publication provides clinicians and researchers with a comprehensive overview of the therapy’s potential, supporting further evaluation and discussion within the medical community.
Importantly, publication in a journal such as “Expert Opinion on Investigational Drugs” places HyBryte within a broader scientific dialogue focused on emerging therapies. Journals of this type are widely read by clinicians and researchers, helping to disseminate new findings and inform future research directions. This level of visibility can play a meaningful role in shaping how new therapies are perceived and ultimately adopted in clinical practice.
Beyond HyBryte, Soligenix continues to apply its broader platform-based approach to drug development across multiple therapeutic areas, including rare diseases and inflammatory conditions. The company’s focus on generating and publishing clinical data reflects an ongoing commitment to scientific rigor as it advances its pipeline.
As the healthcare industry increasingly emphasizes evidence-based medicine, the importance of peer-reviewed research continues to grow. Soligenix’s recent publication represents more than a dissemination of data; it signals progress in the validation of a potential new therapy for a difficult-to-treat disease. By contributing to the scientific literature, the company not only advances its own clinical programs but also supports the broader effort to improve treatment options for patients living with rare and chronic conditions.
For more information, visit www.Soligenix.com.
NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX
About QualityStocks
QualityStocks (“QS”) is a specialized communications platform with a focus on private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, QS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, QS brings its clients unparalleled recognition and brand awareness. QS is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-published: https://www.QualityStocks.com/Disclaimer
QualityStocks
Austin, Texas
www.QualityStocks.com
512.354.7000 Office
Editor@QualityStocks.com
QualityStocks is powered by IBN